Clinical Trials
21 trialsNCT07609940 2026-05-27
POPLIN
Regeneron Pharmaceuticals
Phase 4 Not yet recruiting
NCT06057402 2026-05-14
MagnetisMM15
Pfizer
Phase 4 Recruiting
NCT03934684 2026-05-11
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Phase 4 Completed
NCT05201781 2026-05-08
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Janssen Research & Development, LLC
Phase 4 Recruiting
NCT07030517 2026-05-08
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Johnson & Johnson Private Limited
Phase 4 Recruiting
NCT03173092 2026-05-04
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
Takeda
Phase 4 Terminated
NCT05160922 2026-03-30
Crizotinib Continuation Clinical Study
Pfizer
Phase 4 Active not recruiting
NCT03768960 2025-02-03
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
Johnson & Johnson Private Limited
Phase 4 Completed
NCT06425276 2024-05-23
Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
CASI Pharmaceuticals (China) Co., Ltd.
Phase 4 Completed
NCT05545202 2024-04-03
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
Pharmacosmos A/S
Phase 4 Unknown
NCT05183139 2022-05-03
US MM-7
Takeda
Phase 4 Withdrawn
NCT00622505 2021-05-26
Z-MARK
Novartis
Phase 4 Completed
NCT00211211 2017-12-08
FREE Study - Fracture Reduction Evaluation
Medtronic Spinal and Biologics
Phase 4 Completed
NCT00434447 2017-02-27
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT01410929 2017-01-20
MM
Merit Medical Systems, Inc.
Phase 4 Withdrawn
NCT02268890 2016-07-11
A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
Johnson & Johnson Taiwan Ltd
Phase 4 Completed
NCT00242528 2015-04-14
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
Novartis
Phase 4 Withdrawn
NCT00352703 2014-11-03
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
Swedish Orphan Biovitrum
Phase 4 Completed
NCT00029224 2012-02-01
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Novartis
Phase 4 Completed
NCT00104104 2011-06-29
A Multiple Myeloma Trial in Patients With Bone Metastases
Novartis
Phase 4 Completed
NCT00257114 2008-02-11
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
Millennium Pharmaceuticals, Inc.
Phase 4 Completed